Insulin resistance and, consequently, the reduced insulin response capacity of the target cells, subjects the tissues to an inadequate lipogenic action, which promotes obesity, hepatic production of triglycerides and the release of very low-density lipoproteins (VLDLs), resulting in the development of dyslipidemia. This evidence concerns the gene INS and metabolic syndrome.